

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 35 of 35 returned.**

-
- ☐ 1. 20090028793. 21 Feb 07. 29 Jan 09. Vascular Tumor Markers. Neri; Dario, et al. 424/9.1; 424/139.1 435/320.1 435/367 435/7.23 436/501 530/350 530/387.3 530/387.9 536/23.1 A61K39/395 20060101 A61K49/00 20060101 A61P31/00 20060101 C07K14/00 20060101 C07K16/18 20060101 C12N15/00 20060101 C12N15/11 20060101 C12N5/06 20060101 G01N33/566 20060101 G01N33/574 20060101
-
- ☐ 2. 20080056997. 31 Oct 05. 06 Mar 08. Antibodies Against Tenascin-C. Brack; Simon, et al. 424/9.6; 424/139.1 435/325 435/69.1 530/387.9 536/23.5 A61K39/395 20060101 A61K49/00 20060101 C07H21/04 20060101 C07K16/18 20060101 C12N5/06 20060101 C12P21/04 20060101
-
- ☐ 3. 7273924. 23 May 97; 25 Sep 07. Antibodies to the ED-B domain of fibronectin, their construction and uses. Neri; Dario, et al. 530/387.1; 424/130.1 424/133.1 424/134.1 424/135.1 424/138.1 424/139.1 424/141.1 424/142.1 424/143.1 530/300 530/350 530/385 530/386 530/387.3 530/387.7 530/388.1 530/388.15. A61K38/00 20060101 C07K14/00 20060101 C07K16/00 20060101 C07K17/00 20060101 C07K2/00 20060101 C07K4/00 20060101 C07K5/00 20060101 .
-
- ☐ 4. 7109301. 19 Apr 00; 19 Sep 06. Tenascin-C isoform as marker for neoplasias. Zardi; Luciano. 530/387.1; 424/130.1 435/7.1 530/387.3 530/387.7 530/388.1 530/388.8 530/388.85 530/391.1 530/391.3. A61K39/395 20060101 C07K16/00 20060101 C07K17/00 20060101 C12P21/08 20060101 G01N33/53 20060101 .
-
- ☐ 5. WO2007128563A1. 08 May 07. 15 Nov 07. ANTIBODY-TARGETED CYTOKINES FOR THERAPY. NERI, DARIO, et al. C07K014/535;.
-
- ☐ 6. WO2007096142A2. 21 Feb 07. 30 Aug 07. VASCULAR TUMOR MARKERS. NERI, DARIO, et al. G01N033/574;.
-
- ☐ 7. EP001817345A2. 31 Oct 05. 15 Aug 07. ANTIBODIES AGAINST TENASCIN-C. BRACK, SIMON, et al. C07K016/28;.
-
- ☐ 8. WO2006119897A2. 03 May 06. 16 Nov 06. CONJUGATE FOR TARGETING OF DRUG. NERI, DARIO, et al. A61K047/48;.
-
- ☐ 9. EP001719528A2. 22 Feb 01. 08 Nov 06. Compositions and methods for treatment of angiogenesis in pathological lesions. ZARDI, LUCIANO, et al. A61K047/48;.
-
- ☐ 10. EP001663320A1. 01 Sep 04. 07 Jun 06. TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST FIBRONECTIN ED-B. BORSI, LAURA, et al. A61K051/10; A61P035/00.
-
- ☐ 11. WO2006050834A2. 31 Oct 05. 18 May 06. ANTIBODIES AGAINST TENASCIN-C. BRACK, SIMON, et al. C07K016/28;.
-
- ☐ 12. WO2005023318A1. 01 Sep 04. 17 Mar 05. TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY L19 AGAINST FIBRONECTIN ED-B. BORSI, LAURA, et al. A61K051/10; A61P035/00.

-
- ☐ 13. EP001514561A1. 10 Sep 03. 16 Mar 05. Targeting of tumor vasculature using radiolabelled antibody L19 against fibronectin ED-B. A61K051/10;.
-
- ☐ 14. WO003076469A2. 11 Mar 03. 18 Sep 03. SELECTIVE TARGETING OF TUMOR VASCULATURE USING ANTIBODY MOLECULES. BORSI, LAURA, et al. C07K016/00;.
-
- ☐ 15. EP000906426A1. 23 May 97. 07 Apr 99. ANTIBODIES TO THE ED-B DOMAIN OF FIBRONECTIN, THEIR CONSTRUCTION AND USES. NERI, DARIO, et al. C12N015/13; C07K016/18 A61K039/395 C12N001/21 A61K051/10 G01N033/577 G01N033/68.
-
- ☐ 16. WO 2009056268 A1. Use of binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin, for diagnosing and treating rheumatoid arthritis. KASPAR M, et al.
-
- ☐ 17. WO 2009053987 A1. New antibody specific to vascular endothelial growth factor (VEGF) or a fragment comprises an antigen binding portion, useful for treating a disorder or disease associated with VEGF, e.g. retinal disorder. BATES D O, et al.
-
- ☐ 18. WO 2009013619 A2. Use of a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for preparing a medicament or for manufacturing a diagnostic product for treating or diagnosing lung cancer or lymphoma. NERI D, et al.
-
- ☐ 19. AU 2008229789 A1. Conjugate useful for treating angiogenesis associated disease e.g. tumor, comprises binding region specific for extracellular matrix component present in angiogenesis related pathological lesions, and biocidal or cytotoxic substance. BORSI L, et al.
-
- ☐ 20. WO 2009001219 A2. Treating cancer comprises administering an anti-cancer compound and an antibody-interleukin 2 (IL2) conjugate to an individual. KASPAR M, et al.
-
- ☐ 21. WO 2008120101 A2. Use of a binding member that binds Extra Domain-A (ED-A) isoform of fibronectin, for diagnosing and treating tumor metastases. NERI D, et al.
-
- ☐ 22. WO 2007128563 A1. New fusion protein comprises an antibody having specific binding affinity to extracellular domain of oncofetal fibronectin, useful for treating cancer, psoriasis, atherosclerosis, arthritis, or rheumatoid arthritis. DARIO N, et al.
-
- ☐ 23. WO 2007096142 A2. Identifying neovascular structures comprises detecting vascular tumor markers in the mammalian tissue. CHIISTOPH R, et al.
-
- ☐ 24. WO 2006119897 A2. Conjugate for targeting of drug, preferably for manufacture of medicament for inhibiting angiogenesis and/or neoplastic growth, comprises heterodimeric protein having first and second subunits, and contains therapeutic or diagnostic agent. CORNELIA H, et al.
-
- ☐ 25. WO 2006050834 A2. New specific binding member, including antibodies and their fragments, that bind human tenascin-C, useful for treatment or in vivo diagnosis of a proliferative disorder. BRACK S, et al.
-
- ☐ 26. AU 2006200762 A1. Conjugate for treating angiogenesis in pathological lesions, comprises specific binding member specific for extracellular matrix component present in angiogenesis in pathological lesions, and specified molecule. BORSI L, et al.
-

- ☐ 27. WO 2005023318 A1. Specific binding component that binds human ED-B, labeled with isotope and comprising antigen-binding site that comprises antibody VH and VL domain, useful in manufacture of medicament for treating lesion of angiogenesis or tumor. BALZA E, et al.
-
- ☐ 28. EP 1514561 A1. New isotopically labeled specific binding member that binds human ED-B, useful for manufacturing a medicament for treating a lesion of pathological angiogenesis, tumor, or for manufacturing a diagnostic reagent. BALZA E, et al.
-
- ☐ 29. WO 03076469 A2. New specific binding member that binds human ED-B and comprises an antigen-binding site consisting of antibody VH and VL domains, useful for preparing a composition for treating tumors or a lesion of pathological angiogenesis. BALZA E, et al.
-
- ☐ 30. WO 0246455 A2. Novel process for selecting anti-angiogenesis antibody fragments. GIOVANNONI L.
-
- ☐ 31. WO 0196599 A2. Detecting fibronectin isoform B in body fluid of an individual, by binding fibronectin to gelatin on solid support, and determining ability of specific binding member for Extra Domain B to be retained on support. CASTELLANI P, et al.
-
- ☐ 32. WO 0183816 A2. Detecting tumors including occult tumors in individual comprises amplifying nucleic acid of bodily fluid sample taken from individual to detect mRNA encoding extracellular matrix component. NERI D, et al.
-
- ☐ 33. WO 0162298 A2. Novel conjugate for treating lesions, comprises a specific binding member specific for extra-cellular matrix component present in lesions, and a molecule that exerts biocidal/cytotoxic effect on target cells in lesions. ARNEMOLLA B, et al.
-
- ☐ 34. WO 0063699 A1. Ligands used for diagnosis and treatment of human neoplasias, are capable of identifying the tenascin-C isoform containing domain C of tenascin-C. ZARDI L.
-
- ☐ 35. WO 9745544 A1. Binding member specific for ED-B oncofoetal domain of fibronectin used for tumour diagnosis, and in tumour therapy. BALZA E, et al.
-

[Generate Collection](#)
[Print](#)

Term	Documents
\$PHILOGEN\$	0
OLEPHILOGENIC	1
OLEOPHILOGENIC	3
PEDRO-PHILOGENE	9
PHILOGEN	34
HYDROPHILOGENIC	3
OLEOPHILOGENIC	3
ELOPHILOGENIC	1
HYDROPHILOGENIC	1
PEDRO-PHILOGENE	52

PHILOGENE-HAISSA	1501
(\$philogen\$.asn.).PGPB,USPT,USOC,EPAB,JPAB,DWPI.	35

There are more results than shown above. [Click here to view the entire set.](#)

[Prev Page](#) [Next Page](#) [Go to Doc#](#)